billS1847Event Wednesday, May 21, 2025Analyzed

Association Health Plans Act

Bearish
Impact3/10

Summary

S.1847 is an early-stage bill expanding self-funded association health plans for small businesses, structurally negative for fully insured commercial carriers. The bill has no dollar authorization and remains in committee with only 6 sponsors — near-term passage probability is low. Real market data shows large health insurers (UNH, HUM, CVS, CNC) surging 15-55% in the last 30 days, but this rally is unrelated to S.1847 and driven by broader sector dynamics.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.S.1847 is a structural negative for fully insured commercial carriers but has zero near-term legislative momentum — 11 months with no action since referral to committee.
  • 2.The 30-day rally in health insurers (UNH +41.6%, CNC +54.9%) is unrelated to S.1847; if anything, the bill's reintroduction would be a selling opportunity for the sector.
  • 3.No dollar appropriation; pure regulatory change. Passage probability in the 119th Congress is low given only 6 total sponsors and no committee markups.

Market Implications

Health insurer stocks have rallied dramatically in the last 30 days: UNH at $366.77 (+41.6%), HUM at $229.72 (+35.9%), CNC at $49.57 (+54.9%), MOH at $185.46 (+38.4%). None of this move is driven by S.1847, which is structurally bearish for these same names but lacks passage momentum. Traders should not conflate the sector rally with AHP legislation risk. If S.1847 gained committee traction, it would be a near-term headwind for $CNC and given their exposure to the small group risk pool.

Full Analysis

The Association Health Plans Act (S.1847) was introduced May 21, 2025 by Sen. Rand Paul (R-KY) and referred to the HELP Committee. It is an early-stage bill with 5 cosponsors and no committee markup. The text amends ERISA Section 3(5) to allow trade and professional associations — including those with members across multiple industries — to sponsor self-funded health plans for small employers. This effectively bypasses ACA community rating requirements and state benefit mandates for participants. There is no funding mechanism in this bill — it is purely a regulatory exemption. The Congressional Budget Office would need to score it as a change in tax treatment (self-funded plans are exempt from some ACA taxes). The bill has not moved in 11 months, signaling low legislative priority in the 119th Congress. A companion bill (HR2528) advanced to the Union Calendar in the House, but the Senate bill remains stalled. Structural winners: companies that administer self-funded plans (TPAs like $EIGI, $HSTM) and stop-loss carriers ($CNO, $MHLD). Structural losers: fully insured carriers exposed to the small group and individual markets — (UnitedHealthcare), $CVS (Aetna), $CNC (Centene/Ambetter). and $MOH have less direct exposure. The executive order on psychedelic therapies (Apr 18, 2026) is unrelated to this bill. Real market data shows a massive 30-day rally across the health insurance sector: UNH +41.6%, HUM +35.9%, CVS +15.5%, CNC +54.9%, MOH +38.4%. This rally is not attributable to S.1847 — which is negative for these stocks — but likely reflects broader tailwinds (Medicare Advantage rate finalization, Medicaid redetermination stabilization, or a general risk-on rotation). The bill's absence from the legislative calendar for nearly a year supports the view that it is a low-probability event.

Intelligence Surface

Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures

Strong

Multiple independent sources confirm this signal’s market thesis

Confirmed by:
$$CVS▼ Bearish
Est. $300.0M$1.5B revenue impact

What the bill does

Regulatory exemption allowing small business association health plans (AHPs) to self-fund under relaxed ERISA standards, bypassing ACA market rules and state benefit mandates.

Who must act

Small employers (under 50 employees), trade associations, and professional groups forming self-funded AHPs.

What happens

Lower premium costs for participating small businesses, driving migration of ~3-5% of the small group (2-50 lives) commercial risk pool away from fully insured exchange and off-exchange plans over 3-5 years if enacted.

Stock impact

Aetna (CVS Health) is a top-3 fully insured small group carrier. Membership losses in a ~$15B Aetna commercial block would reduce premium revenue and PBM drug claims flowing through Caremark; 1% membership loss = ~$150M premium impact.

$$CNC▼ Bearish
Est. $400.0M$2.0B revenue impact

What the bill does

Regulatory exemption allowing small business association health plans (AHPs) to self-fund under relaxed ERISA standards, bypassing ACA market rules and state benefit mandates.

Who must act

Small employers (under 50 employees), trade associations, and professional groups forming self-funded AHPs.

What happens

Lower premium costs for participating small businesses, driving migration of ~3-5% of the small group (2-50 lives) commercial risk pool away from fully insured exchange and off-exchange plans over 3-5 years if enacted.

Stock impact

Centene is the largest ACA exchange carrier (Ambetter) with ~20% market share; small group and exchange populations overlap significantly. Self-funded AHP migration would shrink the individual and small group risk pool that Centene dominates, reducing premium revenue and raising average risk pool morbidity.

Market Impact Score

3/10
Minimal ImpactModerateMajor Market Event

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.